Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2018 | Denosumab for NSCLC: results from SPLENDOUR

Solange Peters • 19 Oct 2018
ESMO 2018
Lung Cancer Non-Small Cell Lung Cancer Denosumab
SPLENDOUR

Speaking from the European Society for Medical Oncology (ESMO) 2018 Congress, in Munich, Germany, Solange Peters, MD, PhD, of University Hospital Vaudois, Lausanne, Switzerland, gives us an update on the ETOP and EORTC SPLENDOUR trial (NCT02129699) of denosumab for advanced non-small cell lung cancer.

More from Solange Peters

2:01
Unanswered questions on immunotherapy for lung cancer
Solange Peters • 11 Sep 2022
3:09
ESMO 2022: Highlights from the Presidential Symposium
Solange Peters • 11 Sep 2022
3:18
Subgroup analysis of PEARLS/KEYNOTE-091: PD-L1 expression and outcomes of pembrolizumab
Solange Peters • 11 Sep 2022
2:42
Aligning the educational resources put out by ESMO
Solange Peters • 30 Sep 2019

Related Videos

2:45
Assessing operability in NSCLC: challenges and considerations
Mariana Brandao • 18 Apr 2024
2:03
Biomarker detection for early cancer detection
Robert Rintoul • 19 Apr 2024
1:47
Assessing follow-up strategies in post-surgical lung cancer: insights from a Phase III trial
Robert Rintoul • 19 Apr 2024
7:37
What is the optimal follow-up for lung cancer long term survivors?
Robert Rintoul • 19 Apr 2024
The content of VJOncology is intended for healthcare professionals